Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Immunovant stock | $46.19

Own Immunovant stock in just a few minutes.

Fact checked

Immunovant, Inc is a biotechnology business based in the US. Immunovant shares (IMVT) are listed on the NASDAQ and all prices are listed in US Dollars. Immunovant employs 42 staff and has a market cap (total outstanding shares value) of USD$4.9 billion.

How to buy shares in Immunovant

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Immunovant. Find the stock by name or ticker symbol: IMVT. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Immunovant reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$46.19, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Immunovant, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Immunovant. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Immunovant share price

Use our graph to track the performance of IMVT stocks over time.

Immunovant shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$46.19
52-week rangeUSD$8.34 - USD$53.75
50-day moving average USD$49.3688
200-day moving average USD$36.5881
Wall St. target priceUSD$58.27
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.2539

Buy Immunovant shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Immunovant stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Immunovant price performance over time

Historical closes compared with the close of $46.19 from 2020-12-31

1 week (2021-01-14) 3.77%
1 month (2020-12-24) -7.21%
3 months (2020-10-22) 10.93%
6 months (2020-07-22) 80.64%
1 year (2020-01-22) 189.41%
2 years (2019-01-20) N/A
3 years (2018-01-20) N/A
5 years (2016-01-20) N/A

Immunovant financials

Gross profit TTM USD$0
Return on assets TTM -20.08%
Return on equity TTM -38.23%
Profit margin 0%
Book value N/A
Market capitalisation USD$4.9 billion

TTM: trailing 12 months

Shorting Immunovant shares

There are currently 1.3 million Immunovant shares held short by investors – that's known as Immunovant's "short interest". This figure is 8.7% down from 1.4 million last month.

There are a few different ways that this level of interest in shorting Immunovant shares can be evaluated.

Immunovant's "short interest ratio" (SIR)

Immunovant's "short interest ratio" (SIR) is the quantity of Immunovant shares currently shorted divided by the average quantity of Immunovant shares traded daily (recently around 352219.27374302). Immunovant's SIR currently stands at 3.58. In other words for every 100,000 Immunovant shares traded daily on the market, roughly 3580 shares are currently held short.

However Immunovant's short interest can also be evaluated against the total number of Immunovant shares, or, against the total number of tradable Immunovant shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Immunovant's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Immunovant shares in existence, roughly 10 shares are currently held short) or 0.0249% of the tradable shares (for every 100,000 tradable Immunovant shares, roughly 25 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Immunovant.

Find out more about how you can short Immunovant stock.

Immunovant share dividends

We're not expecting Immunovant to pay a dividend over the next 12 months.

Immunovant overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site